Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

General Information

Immuron Limited
IMC
http://www.immuron.com
Pharmaceuticals
19
75

Current Price Data+

Current Price Open High Low Last Close Volume Price Movement
$0.26 $0.27 $0.27 $0.26 $0.26 44800 - ( No change )
  • +Security prices are delayed by least 20 minutes and are indicative only.

Company Overview

Business Description
Immuron Limited (IMC) is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. IMC’s products ranges target infectious diseases of the gastrointestinal tract, chronic diseases such as fatty liver/NASH, and influenza. IMC has one product in the market, Travelan, for preventing travellers’ diarrhoea and seven products under research and development process.
Strategy Analysis
--

Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2014 A -2.5 -6.1 0.0% 0.0 0.0 0.0% 0.0%
2013 A -3.5 -24.9 0.0% 0.0 0.0 0.0% 0.0%
2012 A -2.3 -16.7 0.0% 0.0 0.0 0.0% 0.0%

Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2012 A 2013 F 2014 F 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F
Acrux Limited (ACR) $141M 3.0384 -0.6083 0.1581 5.0298 12.8419 11.0892 9.47% 8.62% 8.30%
Immuron (IMC) $20M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Mayne Pharma Group (MYX) $809M 1.0457 -0.2428 1.2152 32.9073 43.4599 19.6190 0.00% 0.00% 0.00%

Financial Summary

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 2.87 0.00
Market 0.92 14.80 1.04 1.09
Sector 0.83 16.80 2.79 1.35

Directors

Name Position Start Date
Dr Roger Aston Non-Executive Chairman 25/05/2012
Mr Daniel Pollock Non-Executive Director 11/10/2012
Mr Stephen Anastasiou Non-Executive Director 28/05/2013

Management

Name Position
Leearne Hinch Chief Executive Officer
Peter Vaughan Joint Company Secretary
Phillip Hains Joint Company Secretary

Substantial Shareholders

Holding Name
376,380,011 (12.56%) Grandlodge Pty Ltd
71,250,000 (6.88%) Inverarey Pty Ltd
59,164,094 (5.71%) Hadasit Medical Research Services & Development Ltd

Calendar of Events

Date Event
17 February 2016 Report (Interim)
28 August 2015 Report (Prelim)
28 August 2015 Report (Annual)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/fsg.asp.